Composition
lnj 3 mg: Per ml: Granisetron (as HCI) 1 mg; soln in 3 ml (3 mg)/1 ml (1 mg) amp. Tab 1 mg: Granisetron (as HCI) 1 mg. Liqd: Per 5 ml: Granisetron (as HCI) 1 mg. Patches: Per patch: Granisetr
Indications & Dosage
Nausea and vomiting induced by cytotoxic chemotherapy: BY TRANSDERMAL PATCHES: Adult: For planned duration of 3-5 days where oral antiemetics cannot be used, apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24-48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy Prevention of postoperative nausea and vomiting: BY IV INJ: Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5ml and given over 30 seconds Treatment of postoperative nausea and vomiting: BY IV INJ: Adult: 1 mg, dose to be diluted to 5ml and given over30 seconds; max. 3 mg per day Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy: ORAL: Adult: 1-2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1-2 divided doses for up to 1 week following treatment, when IV route also used, max. combined total dose 9mg in24 hours BY IV INJ, OR BY IV INF: Adult: 10-40 mcg/kg (max. per dose 3 mg), tobe given 5 minutes before start of treatment, dose maybe repeated if necessary, further maintenance doses must not be given less than 10 minutes apart; max. 9 mg per day. Children: Not recommended.
Administration
For IV injection, each 1 mg Granisetron diluted to 5ml and given over not less than 30 seconds, for IV infusion, to be given over 5 minutes.
Compatibility
Stable in D5 Ys NS, D5NS, D5W, NS, bacteriostatic water, incompatible with amphotericin (Y-site ad-ministration).
Stability
Store at 25C-30C. Do not freeze vials. Protect from light. Stable when mixed in NS or D5W for 7 days under refrigeration and for 3 days at room temperature.
Precautions
Hepatic impairment, Sub-acute intestinal obstruction, susceptibility to QT-interval prolongation (including electrolyte disturbances).
Pregnancy
Caution advised
Lactation
Not recommended.
Side Effects
Constipation, diarrhoea, headache, insomnia, transient rise in liver enzymes, extrapyramidal reactions, QT-interval prolongation, rash, with transdermal use application-site reactions.